Literature DB >> 6626414

Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

E Pike, P Kierulf, B Skuterud, J E Bredesen, P K Lunde.   

Abstract

The relative role of lipoproteins, albumin and orosomucoid in the serum binding variation of various drugs was examined by separate removal of these proteins. Lipoproteins were removed from serum by ultracentrifugation, albumin by affinity chromatography and orosomucoid by immunoprecipitation. Removal of the lipoproteins did not affect the serum binding of the acidic (phenytoin) and neutral (digitoxin) drugs tested, nor the basic drugs disopyramide, quinidine or propranolol. A reduction in binding of amitryptyline, nortriptyline, doxepin and desmethyldoxepin was observed. Removal of albumin did, with some exception for nortriptyline, not affect the serum binding of the basic drugs tested. A pronounced reduction in the binding of phenytoin and digitoxin was observed. Removal of orosomucoid did not affect the binding of the acidic and neutral drugs tested. A reduction in the binding of all the basic drugs tested was observed, especially for disopyramide whose binding almost disappeared. Quinidine, propranolol, phenytoin and digitoxin all bound to isolated lipoproteins, but the removal of lipoproteins had no effect on the total serum binding for these drugs. Hence, the use of deficient sera provides valuable information as to the quantitative role of the various proteins in drug binding, whereas studies using purified proteins are often necessary to examine the mechanisms of the drug protein interactions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626414      PMCID: PMC1427992          DOI: 10.1111/j.1365-2125.1983.tb02155.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Factors affecting the binding of tricyclic tranquillizers and antidepressants to human serum albumin.

Authors:  D Sharples
Journal:  J Pharm Pharmacol       Date:  1976-02       Impact factor: 3.765

2.  The binding of quinidine to protein fractions of normal human sera.

Authors:  O G Nilsen; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1975-05-01       Impact factor: 5.858

3.  Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma.

Authors:  J Travis; J Bowen; D Tewksbury; D Johnson; R Pannell
Journal:  Biochem J       Date:  1976-08-01       Impact factor: 3.857

4.  Correlation of physicochemical properties with absorption and metabolism of some tricyclic drugs.

Authors:  A Gescher; A Li Wan Po
Journal:  J Pharm Pharmacol       Date:  1978-06       Impact factor: 3.765

5.  Agarose gel electrophoresis.

Authors:  B G Johansson
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

6.  Two dimensional immunoelectrophoresis of human serum proteins for the investigation of protein drugs.

Authors:  R L Kramer; A Richens
Journal:  Br J Pharmacol       Date:  1972-05       Impact factor: 8.739

7.  Binding of reserpine to plasma albumin and lipoproteins.

Authors:  Z Chen; A Danon
Journal:  Biochem Pharmacol       Date:  1979       Impact factor: 5.858

8.  Propranolol binding to serum orosomucoid.

Authors:  B J Scott; A R Bradwell; R E Schneider; H Bishop
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

9.  Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein.

Authors:  O G Nilsen; P Leren; I Aakesson; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

10.  Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias.

Authors:  R E Kates; T D Sokoloski; T J Comstock
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

View more
  8 in total

Review 1.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.

Authors:  J L Caplin; A Johnston; J Hamer; A J Camm
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

6.  The protein binding of timegadine determined by equilibrium dialysis.

Authors:  S George; A McBurney; J Ward
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

8.  Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis.

Authors:  C B Kristensen; L F Gram; P Kragh-Sørensen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.